United Therapeutics Corpo... (UTHR)
NASDAQ: UTHR
· Real-Time Price · USD
310.86
9.44 (3.13%)
At close: May 12, 2025, 3:59 PM
310.91
0.02%
After-hours: May 12, 2025, 04:41 PM EDT
United Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adcirca Revenue | 23.8M | 28.9M | 325.1M | 55.9M | 67.3M | 107.2M | 323.7M | 419.7M | 372.2M | 278.83M | 221.47M | 176.97M | 122.54M | 70.58M |
| Adcirca Revenue Growth | -17.65% | -91.11% | +481.57% | -16.94% | -37.22% | -66.88% | -22.87% | +12.76% | +33.49% | +25.90% | +25.14% | +44.42% | +73.62% | n/a |
| Orenitram Revenue | 434.3M | 359.4M | 13.8M | 306.1M | 293.1M | 225.3M | 205.1M | 185.8M | 157.2M | 118.43M | 41.27M | 491.18M | 457.97M | 430.13M |
| Orenitram Revenue Growth | +20.84% | +2504.35% | -95.49% | +4.44% | +30.09% | +9.85% | +10.39% | +18.19% | +32.73% | +186.99% | -91.60% | +7.25% | +6.47% | n/a |
| Product and Service, Other Revenue | 22.1M | 11.8M | 500.2M | 513.7M | 516.7M | 587M | 599M | 670.9M | 602.3M | 572.79M | 553.73M | 438.79M | 325.61M | 240.38M |
| Product and Service, Other Revenue Growth | +87.29% | -97.64% | -2.63% | -0.58% | -11.98% | -2.00% | -10.72% | +11.39% | +5.15% | +3.44% | +26.19% | +34.76% | +35.46% | n/a |
| Remodulin Revenue | 538.1M | 494.8M | 873M | 607.5M | 122.9M | 113.7M | 84.8M | 372.9M | 404.6M | 470.07M | 463.07M | n/a | n/a | n/a |
| Remodulin Revenue Growth | +8.75% | -43.32% | +43.70% | +394.30% | +8.09% | +34.08% | -77.26% | -7.83% | -13.93% | +1.51% | n/a | n/a | n/a | n/a |
| Tyvaso Revenue | 1.62B | 1.23B | 182.9M | 202.3M | n/a | n/a | n/a | 76M | 62.5M | 20.44M | n/a | n/a | n/a | n/a |
| Tyvaso Revenue Growth | +31.34% | +574.52% | -9.59% | n/a | n/a | n/a | n/a | +21.60% | +205.73% | n/a | n/a | n/a | n/a | n/a |
| Unituxin Revenue | 238.7M | 198.9M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Unituxin Revenue Growth | +20.01% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 170.1M | 162.5M | 219.2M | 177.6M | 144.4M | 132.2M | 127.6M | 130M | 87.3M | 166.1M | 98.4M | 141.5M | 79M | 127.9M | 109.1M | 112.8M | 117.2M | 158.7M | 66.3M | 105.9M | 93M | 105.2M | 99.4M | 39.6M | 92M | 79.2M | 110.1M | 83.1M | -6.6M | 159.1M | 47.2M | 67.4M | 56.4M | 139.5M | 100.1M | 72.2M | 5M | 148.56M | -17.28M | 109.99M | 211.34M |
| Selling, General, and Administrative Revenue Growth | +4.68% | -25.87% | +23.42% | +22.99% | +9.23% | +3.61% | -1.85% | +48.91% | -47.44% | +68.80% | -30.46% | +79.11% | -38.23% | +17.23% | -3.28% | -3.75% | -26.15% | +139.37% | -37.39% | +13.87% | -11.60% | +5.84% | +151.01% | -56.96% | +16.16% | -28.07% | +32.49% | -1359.09% | -104.15% | +237.08% | -29.97% | +19.50% | -59.57% | +39.36% | +38.64% | +1344.00% | -96.63% | -959.93% | -115.71% | -47.96% | n/a |
| Research and Development Revenue | 149M | 133.8M | 103.5M | 139.6M | 104.1M | 151.4M | 84.7M | 89M | 82.9M | 93.9M | 66.1M | 93.9M | 69M | 82.9M | 79.2M | 74.3M | 303.7M | 126.1M | 68.7M | 89.7M | 73.2M | 113.6M | 85.7M | 85.9M | 897.4M | 138.8M | 101.1M | 82.3M | 35.7M | 113.6M | 55M | 59.8M | 36.2M | 66.9M | 45.9M | 35.2M | -400K | 75.95M | 9.53M | 49.41M | 110.21M |
| Research and Development Revenue Growth | +11.36% | +29.28% | -25.86% | +34.10% | -31.24% | +78.75% | -4.83% | +7.36% | -11.71% | +42.06% | -29.61% | +36.09% | -16.77% | +4.67% | +6.59% | -75.54% | +140.84% | +83.55% | -23.41% | +22.54% | -35.56% | +32.56% | -0.23% | -90.43% | +546.54% | +37.29% | +22.84% | +130.53% | -68.57% | +106.55% | -8.03% | +65.19% | -45.89% | +45.75% | +30.40% | -8900.00% | -100.53% | +697.19% | -80.72% | -55.17% | n/a |